Research Appraisaldiagnostic

A novel hybrid framework integrating GA-driven 3D ResUNetGAN for MRI brain tumor segmentation

PloS oneKirubakaran, Muthulakshmi, Mohan, JayalakshmiDOI

Clinical Snapshot

55CEBM
Evidence: Weakdiagnostic

PICO Framework

P — PopulationMRI brain scans from BraTS2023 dataset (437 training, 188 validation cases)
I — InterventionGA-optimized 3D ResUNetGAN segmentation algorithm
C — ComparatorStandard segmentation methods (3D UNet, DynUNet, UNETR, SwinUNETR, standard ResUNet)
O — OutcomesDice similarity coefficient for tumor core (TC), whole tumor (WT), and enhancing tumor (ET) segmentation accuracy

Bottom Line

This study presents a genetic algorithm-optimized deep learning approach for automated brain tumor segmentation achieving high Dice scores (0.91-0.96) on the BraTS2023 dataset. While the technical performance appears promising, the study lacks essential diagnostic accuracy metrics like sensitivity and specificity, confidence intervals, and clinical validation. The computational complexity of genetic algorithm optimization may limit practical implementation. Without proper statistical analysis and real-world validation, clinicians cannot adequately assess the clinical utility or reliability of this segmentation tool. The study represents an incremental technical advance but requires substantial additional validation before clinical adoption.

Evidence: Weak

Key Findings

  • P Value: Not reported

  • Effect Size: Dice scores: TC 0.94, WT 0.96, ET 0.91

  • Primary Outcome: Dice similarity coefficient for tumor segmentation accuracy

  • Nnt Or Sensitivity: Sensitivity and specificity not reported; only Dice coefficients available

  • Confidence Interval: Not reported

Clinical Application

Computationally intensive GA optimization may limit real-time clinical implementation Would require TGA approval as medical device software; integration with existing PACS systems in Australian hospitals needs evaluation Patients requiring brain tumor segmentation from multi-modal MRI

Abstract

Accurate brain tumor segmentation by multi-modal MRI is crucial for diagnosis, treatment planning, and prognostic assessment. This work proposes a novel hybrid architecture within a GA optimized by 3D residual U-Net (ResUNet) with generative adversarial network (GAN) for the accurate segmentation of tumor subregions, namely the tumor core (TC), whole tumor (WT), and enhancing tumor (ET), using a dataset collected from BraTS2023 (437 training and 188 validation). By using GAs, we enable the computer to automatically find the best model structure and training settings, which helps keep the model simple enough to avoid overfitting while being powerful enough to generalise well to new data. The GAN part of our method trains the model to draw more realistic and consistent boundaries around tumor regions in MRI scans, thereby improving the overall quality of the segmentation. In our experiments, this GA-ResUNetGAN approach performed better than several leading methods, such as 3D UNet, DynUNet, UNETR, SwinUNETR, and the standard ResUNet, especially in accurately identifying TC, WT, and ET parts-achieving Dice scores of 0.94, 0.96, and 0.91 on the validation set. In addition, K-Fold cross-validation was performed to ensure consistent performance across different data splits. While the method involves more processing work than some baseline techniques, it provides improved segmentation quality and boundary delineation on the evaluated dataset. These results demonstrate the advantages of combining evolutionary optimization with adversarial deep learning for challenging medical imaging tasks.

References

  1. 1.Kirubakaran, Muthulakshmi, Mohan, & Jayalakshmi. (2026). A novel hybrid framework integrating GA-driven 3D ResUNetGAN for MRI brain tumor segmentation. PLoS One. https://doi.org/10.1371/journal.pone.0349451
Share:XLinkedIn

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service